

MSK Levels of Evidence

OncoKB
J Clin Oncol 34, 2016 (suppl; abstr 11583)

Level 1

FDA-recognized biomarker predictive of response to an **FDA-approved** drug in this indication

Level 2A

Standard-of-care biomarker predictive of response to an **FDA-approved** drug in this indication

Level 2B

Standard-of-care biomarker predictive of response to an **FDA-approved** drug **in another indication**, but not standard-of-care for this indication

Level 3A

Compelling clinical evidence supports the biomarker as being predictive of response to a drug **in this indication**, but neither biomarker nor drug are standard-of-care

Level 3B

Compelling clinical evidence supports the biomarker as being predictive of response to a drug **in another indication**, but neither biomarker nor drug are standard-of-care

Level

Compelling biological evidence supports the biomarker as being predictive of response to a drug, but neither biomarker nor drug are standard-of-care

Standard Therapeutic Implications

*Includes biomarkers
that are recommended
as standard of care
by the NCCN or
other expert panels
but not necessarily
FDA-recognized
for a particular
indication

Investigational
Therapeutic
Implications
possibly directed
to clinical trials

Hypothetical
Therapeutic
Implications
based on
preliminary, nonclincial data

Standard-of-care biomarker predictive of resistance to an **FDA-approved** drug **in this indication**

Level R1 Standard Therapeutic Implications